Facebook Pixel Code
SPARC BioCentre banner
SPARC BioCentre

Chemical & Small Molecule Libraries

Small Molecule Libraries

SPARC has a number of small molecule collections available for HTS. To maintain the integrity of our collections, we do not allow cherry-picking of compounds until after HTS, once a hit list is established.  

In general, we do not offer these collections as aliquots for purchase by investigators, but are happy to screen them against your assay here at SPARC. In special circumstances where we do not have the instrumentation to perform your assay at SPARC, we will consider selling a small aliquot (2.5 nL – 1 L) at market value.

Approved/Bioactive/Natural Product Collections

This class of compounds is composed of approved drugs, bioactive molecules (with known targets) and natural products from three sources (LOPAC, Spectrum and Prestwick).

Prestwick Collection – 1280 compounds
The Prestwick library contains 100 per cent approved drugs (FDA, EMA and other agencies) selected by medicinal chemists and pharmacists for their high chemical and pharmacological diversity as well as for their known bioavailability and safety in humans.

Microsource Spectrum Collection – 2400 compounds
These compounds were selected by medicinal chemists and biologists so as to provide a wide range of biological activities and structural diversity. Spectrum includes compounds from the Pharmakon, Discover, and NatProd Collections, thereby providing the opportunity to evaluate drugs and biochemical tools with known biological profiles and explore the potential of novel structural diversity manifest in pure natural products.

  • PHARMAKON 1600 is a combination of all the compounds from the US and International Drug Collections.  The compounds have reached clinical evaluation and not simply demonstrated biological activity experimentally. Most of the constituent drugs are still in the market, and literature references and toxicology information is available. 
  • DISCOVER collection is comprised of compounds that have shown biological potential in peer-reviewed publications but have never led to their development as drugs in human diseases.
  • The natural product (NatProd) collection of compounds is derived from commercial sources. All are fully characterized according to literature reports, and compounds are included on the basis of structural and chemical class.

LOPAC 1280 (Sigma) – 1280 compounds
(Library of Pharmacologically Active Compounds) This annotated collection contains marketed drugs, failed development candidates and “gold standards” that have well-characterized activities. These compounds are the result of lead optimization efforts and possess great value, having been rationally designed by structure-activity relationship (SAR) studies. While LOPAC 1280 spans a broad range of cell signaling and neuroscience areas, molecules that interact with G protein-coupled receptors (GPCRs) make up over 50 per cent of the compounds in this collection.

Drug-like Collections

Chembridge DIVERSet – 50,000 compounds
DIVERset compounds exhibit extensive pharmacophore coverage and chemical diversity, making it an ideal tool for primary screening.

Maybridge HitFinder – 14,400 compounds
The HitFinder collection represents the drug-like diversity of the Maybridge Screening Collection, offering easy and rapid lead identification. Compounds fit Lipinski guidelines for "drug-likeness” and were selected to be non-reactive, ensuring fewer false positives and higher quality results.

Drug-like pilot screen – 2400 compounds
These molecules are either from the Chembridge DIVERset or Maybridge HitFinder collection.
This smaller subset of the drug-like collection was assembled by the SPARC team and covers the structural diversity of the large collection, thus allowing for the generation of preliminary screening data at low cost.

GlycoNet collection – 69,000 compounds
Our newest library consists of 24,000 compounds from ChemBridge and 45,000 compounds from Enamine. Compounds were selected to have no structural overlap with our existing collections and with PAINS filters applied, thus increasing the likelihood of identifying a novel hit compound that can be developed into a lead.

Collections attained from the Ontario Institute of Cancer Research (OICR)

OICR Kinase Inhibitor Library – 560 compounds
This collection contains compounds targeting protein kinases, lipid kinases and some outstanding inhibitors. The compounds are all known and public structures.

OICR Tool Kit – 400 compounds
A collection of inhibitors, many of which reached clinical phase development or exist as marketed therapeutics. This collection includes PARP inhibitors, STAT3 inhibitors, and a number of other anti-cancer or chemotherapeutic compounds.  

Prestwick Phytochemical Library – 320 compounds
A collection of 320 natural products, mostly derived from plants, assembled by medicinal chemists and rich in diverse chemotypes, thus realistic for follow-up chemistry.

Peptidomimetic Library – 3000 compounds
Selected by OICR from ChemDiv's Non-peptide Peptidomimetics library. These compounds are α-helix or β/γ-turn mimetics based on several combinatorial templates modified with both flexible and rigid substituent.

Microsource Natural Products library – 800 compounds
There is 88% overlap between this collection and the larger Microsource Spectrum collection.

Tocris Library – 1185 compounds
A collection of biologically active compounds, there is some overlap between this library and the Prestwick (9%), LOPAC (27%), and Microsource Spectrum (12%) collections.